直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 110673
著者
オカモト, マサト Second Department of Oral and Maxillofacial Surgery, Tokushima University School of Dentistry
佐藤, 光信 Second Department of Oral and Maxillofacial Surgery, Tokushima University School of Dentistry 徳島大学 教育研究者総覧 KAKEN研究者をさがす
キーワード
anti-cancer immunity
Toll-like receptor (TLR)
Bacterial CpG-DNA
OK-432
plant-derived protein
資料タイプ
学術雑誌論文
抄録
It is important to augment the anti-cancer host response in cancer treatment. Recent studies suggested that the signaling via Toll-like receptors (TLRs) which are newly identified receptor molecules recognizing many pathogens, are involved in the induction of anti-cancer immunity. Seya et al. demonstrated that maturation of dendritic cells(DCs) and cytokine induction by the cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin (BCG-CWS) are induced via both TLR2 and TLR4. Akira et al. discovered a new molecule of TLR family, TLR9, recognizing unmethylated bacterial CpG-DNA, whose clinical use is expected for cancer therapy as a potent inducer of a helper T cell 1 (Th1)-typeT-cell response. TLR9-deficient mice did not show any responses to CpG-DNA, including Th 1 cytokine production and maturation of DCs. We have obtained two molecules, a lipoteichoic
acid-related molecule isolated from streptococcal agent OK-432, and a plant-derived 55-kDaprotein that can induce Th1 response and elicit a strong anti-cancer effect in vivo and in vitro. Our basic experiments demonstrate that TLR4 signaling is intimately involved in anti-cancer immunity induced by these immunopotentiators. Our clinical examination in oral cancer patients also suggests the requirement of both TLR4 and MD-2 in the OK-432-inducedanti-cancer host response. Establishment and clinical use of the methodology for human cancer therapy by utilizing TLR signaling is greatly expected.
掲載誌名
The journal of medical investigation : JMI
ISSN
13431420
cat書誌ID
AA11166929
50
1-2
開始ページ
9
終了ページ
24
並び順
9
発行日
2003
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
歯学系